Prehospital Treatment of Status Epilepticus in the United States

JAMA ◽  
2021 ◽  
Vol 326 (19) ◽  
pp. 1970
Author(s):  
Elan L. Guterman ◽  
James F. Burke ◽  
Karl A. Sporer
Epilepsia ◽  
2005 ◽  
Vol 46 (s11) ◽  
pp. 46-48 ◽  
Author(s):  
Giancarlo Logroscino ◽  
Dale C. Hesdorffer ◽  
Gregory Cascino ◽  
W. Allen Hauser ◽  
Alessandra Coeytaux ◽  
...  

Seizure ◽  
2019 ◽  
Vol 71 ◽  
pp. 295-303 ◽  
Author(s):  
Iván Sánchez Fernández ◽  
Marta Amengual-Gual ◽  
Cristina Barcia Aguilar ◽  
Tobias Loddenkemper

2020 ◽  
Vol 112 ◽  
pp. 107459
Author(s):  
Mei Lu ◽  
Mareva Faure ◽  
Aurore Bergamasco ◽  
William Spalding ◽  
Arturo Benitez ◽  
...  

2020 ◽  
Vol 40 (06) ◽  
pp. 652-660
Author(s):  
Assia Meziane-Tani ◽  
Brandon Foreman ◽  
Moshe A. Mizrahi

AbstractStatus epilepticus is one of the most common neurological emergencies and is likely to have increasing prevalence in coming years given an aging “baby boomer” population in the United States. Because status epilepticus is associated with significant morbidity and mortality, identification and treatment are paramount. Care should be taken to exclude nonorganic mimics and infectious and metabolic causes. Status epilepticus can be classified into stages with associated recommendations for escalation in therapy, increasing from push-dose benzodiazepines to continuous anesthetic infusions and other nontraditional therapies. Concurrent electroencephalogram monitoring helps to identify, localize, and assess resolution of ictal patterns alongside antiseizure drug administration. A protocol is proposed for the management of status epilepticus in a step-wise fashion.


2013 ◽  
Vol 41 (8) ◽  
pp. 1853-1862 ◽  
Author(s):  
Jacqueline Urtecho ◽  
Meredith Snapp ◽  
Michael Sperling ◽  
Mitchell Maltenfort ◽  
Matthew Vibbert ◽  
...  

Critical Care ◽  
2011 ◽  
Vol 15 (S1) ◽  
Author(s):  
J Urtecho ◽  
A Seifi ◽  
M Maltenfort ◽  
M Vibbert ◽  
W McBride ◽  
...  

2020 ◽  
Vol 165 ◽  
pp. 106346
Author(s):  
Monica B. Dhakar ◽  
David J. Thurman ◽  
Hiba A. Haider ◽  
Andres R. Rodriguez ◽  
Nathalie Jette ◽  
...  

1987 ◽  
Vol 8 (9) ◽  
pp. 260-286

Amoxapine is a popular antidepressant that has been marketed in the United States since 1980. It is a tricyclic dibenzoxapine that is reported to have a rapid antidepressant effect and limited toxicity as compared with other tricyclic antidepressants. In a review of the outcome of 479 cyclic antidepressant overdoses that were reported to two poison control centers during an 18-month period, the mortality rate associated with overdoses was 23 times greater than the mortality associated with overdoses of the other cyclic antidepressants (15.2% v 0.77%). Persistent and poorly controllable seizures, which occurred eight times more frequently than with other antidepressants, were the most profound toxic effect (36.4%). Hyperthermia was reported in several cases (9.1%) due to status epilepticus.


Sign in / Sign up

Export Citation Format

Share Document